CAMBRIDGE, Mass.--(BUSINESS WIRE)--Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the fields of cancer metabolism and rare metabolic genetic diseases, today announced that David Schenkein, M.D., chief executive officer, is scheduled to present at the UBS Global Life Sciences Conference on Thursday, September 20, 2012 at 2:30PM EST at the Grand Hyatt in New York City.
